HOUSTON, Texas, August 8, 2012—ZZ Biotech, LLC today announced that it has commenced dosing healthy volunteers in a Phase 1 clinical study with 3K3A-APC, a recombinant variant of human activated protein C (APC), being developed for the treatment of acute ischemic stroke. The Phase 1 study is a randomized, double-blind, placebo-controlled, single-center trial that will…

Read More

Clinical safety trials in humans to start this summer LOS ANGELES, July 17, 2012 — A team led by a physician-scientist at the University of Southern California (USC) has created an experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally approved clot-busting therapy. Clinical trials to test…

Read More